Friday 10 July 2015, Amsterdam
"The report, now available on ASDReports, “Vaccine Market by Technology (Live Attenuated, Toxoid, Conjugate, Subunit, Synthetic, Dendritic Cell, Inactivated), Type (Preventive, Therapeutic), End User (Pediatrics, Adults), Disease Indication (Infectious Disease, Cancer, Allergy) - Forecasts to 2019”, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the vaccines market along with the estimates and forecasts of the revenue and market share analysis.
The report segments this market on the basis of type, technology, disease indication, and end user. Among various end users, the pediatrics segment is expected to account for the largest share of the market and is expected to grow at the highest CAGR from 2014 to 2019. Growth in this segment can be attributed to the rising prevalence of diseases and the increasing number of initiatives taken by government organizations for vaccination programs.
Based on geography, the global vaccines market is segmented into North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share of the market during the forecast period. Growth of this market is driven by factors such as increasing government support for vaccine development, rising company investments for vaccine research, and high prevalence of diseases.
Key players in the vaccines market include Bavarian Nordic (Denmark), CSL Limited (Australia), Emergent BioSolutions Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson and Johnson (U.S.), MedImmune, LLC (U.S.), Merck and Company (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Sanofi Pasteur (France).
Publish date : January 2015
Report code : ASDR-208180
Pages : 211